Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track

Executive Summary

Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said

You may also be interested in...



Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks

As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry

Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks

As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry

GSK Cervarix Setback: FDA Questions On HPV Vaccine Bode Well For Merck

The launch of GlaxoSmithKline human papilloma virus vaccine Cervarix will be further delayed behind Merck's competing Gardasil vaccine after FDA issued a "complete response" letter related to the BLA Dec. 17

Related Content

Latest News
UsernamePublicRestriction

Register

PS048942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel